Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.65 |
| ▸ | DRD2 | P14416 | 4/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514784 | 0.86 | DRD2 (0.62) | DRD4DRD2DRD3LMNAADRA1B | |
| SCHEMBL14514768 | 0.81 | DRD2 (0.73) | DRD4DRD2DRD3MAPTSLC6A4 | |
| SCHEMBL2250914 | 0.77 | HTR2A (0.88) | DRD4DRD2DRD3SLC6A4HTR2A | |
| SCHEMBL14559605 | 0.77 | MAPT (0.70) | DRD4DRD2DRD3MAPTLMNA | |
| SCHEMBL11214631 | 0.77 | ADRA1B (0.61) | USP2LMNAADRA1BHTR1AADRA1A | |
| SCHEMBL10367299 | 0.76 | ADRA1B (0.52) | MAPTLMNAADRA1BTP53HTR1A | |
| SCHEMBL10367403 | 0.76 | ADRA1B (0.63) | DRD2DRD3MAPTUSP2LMNA | |
| SCHEMBL22542083 | 0.75 | DRD4 (0.51) | DRD4DRD2DRD3MAPTTP53 | |
| SCHEMBL21985476 | 0.75 | SMN1; SMN2 (0.59) | DRD4DRD2MAPTUSP2LMNA | |
| SCHEMBL861408 | 0.75 | SMN1; SMN2 (0.59) | DRD4DRD2MAPTUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | PFIZER INC. (US) | 2019-03-28 | — | — | US | claimed |
| CN-108348506-A | Include the therapeutic nanoparticle and its preparation and application of therapeutic agent | 辉瑞公司 | 2018-07-31 | — | — | CN | claimed |
| EP-3337516-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2018-06-27 | — | — | EP | claimed |
| WO-2017034991-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2017-03-02 | — | — | WO | claimed |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2025-12-18 | — | — | US | disclosed |
| EP-4547229-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | Universiteit Gent (BE) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024003363-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2024-01-04 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | NPC1L1, NPC1, ABCB4 | DRD4 4572/4885DRD2 4816/4885DRD3 4767/4885 |
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | CTSA, GAA, EEA1 | DRD4 4805/4885DRD2 4865/4885DRD3 4839/4885 |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | DRD4 4805/4885DRD2 4865/4885DRD3 4839/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | DRD4 4704/4885DRD2 4727/4885DRD3 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.